Detrol is a prescription medication marketed in Hong Kong that contains the active ingredient tolterodine. It belongs to the bladder-and-urinary therapeutic class and is available as a pill in strengths of 1 mg and 2 mg. Tolterodine works as an antimuscarinic agent to reduce symptoms of an overactive bladder. Detrol is regulated by the Hong Kong Department of Health and requires a physician’s prescription.
Detrol’s active ingredient, tolterodine, blocks muscarinic receptors-primarily the M₂ and M₃ subtypes-found in the smooth muscle of the urinary bladder. By inhibiting these receptors, the drug reduces involuntary bladder contractions, which lowers urgency, frequency, and episodes of urinary incontinence. The onset of action typically occurs within a few hours after oral administration, while the therapeutic effect can last up to 24 hours, allowing once-daily dosing. Tolterodine is absorbed quickly from the gastrointestinal tract, undergoes hepatic metabolism (primarily via CYP2D6), and is eliminated mainly through the kidneys.
Detrol is approved in Hong Kong for the management of overactive bladder (OAB), defined by symptoms such as urinary urgency, increased frequency, nocturia, and urge urinary incontinence. The medication is indicated for adults who have not achieved adequate symptom control with behavioral therapies alone. Clinical guidelines recommend antimuscarinic agents like tolterodine as first-line pharmacologic treatment for OAB after lifestyle modifications.
If patients are taking multiple medications, they should discuss a full medication review with their pharmacist or physician.
Dosing must be individualized by a healthcare provider, especially in patients with renal or hepatic impairment.
This article provides educational information about Detrol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Detrol may be combined with other bladder agents, such as β-3 agonists, but only under close medical supervision to avoid additive anticholinergic effects and ensure safety.
Sip water frequently, use sugar-free chewing gum or lozenges, and avoid caffeinated or alcoholic beverages that can worsen dryness. If the symptom persists, discuss possible dose adjustment with your clinician.
Yes. Detrol tablets are prescription medicines and can be carried in original packaging with a copy of the prescription. Declare them if required by Hong Kong customs.
In Hong Kong, the 1 mg tablet is typically round and white, while the 2 mg tablet may be round and pink. Always verify the imprint code on the pill against the pharmacist’s label.
Antimuscarinic therapy is generally not recommended for patients with indwelling catheters because bladder dynamics differ; consult your urologist for individualized advice.
Both are antimuscarinic agents for overactive bladder, but Detrol (tolterodine) may have a lower incidence of dry mouth and constipation for some patients. Clinical response varies; a physician can help determine the best option.
Tolterodine is not known to significantly alter blood pressure, but anticholinergic side effects such as dizziness could indirectly affect measurement reliability.
No specific dietary restrictions are required, though a high-fiber diet can help mitigate constipation, a common side effect.
Most patients notice symptom relief within 1 to 2 weeks, with maximal benefit often achieved after 4 weeks of consistent use.
